Jaipur

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Familial hypercholesterolaemia2 trials
• Lung cancer2 trials
• Coronary artery disease1 trial
• IgA nephropathy1 trial
• Metastatic breast cancer1 trial
• Sjögren's disease1 trial
• Stroke1 trial
• Systemic sclerosis (scleroderma)1 trial

Phase

• Phase 35 trials
• Phase 21 trial
• Phase 41 trial

Status

• Active, not recruiting3 trials
• Completed3 trials
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• Novartis Pharmaceuticals8 trials

Running trials

• Recruiting

  Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

  NCT06470048· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Zigakibart in Adults With IgA Nephropathy

  NCT05852938· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Sjögren's disease1 recruiting

Closed trials

• Completed

  A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

  NCT06386419· Phase 4· Novartis Pharmaceuticals· Source

• Terminated

  Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

  NCT05132075· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world

  NCT05022342· Novartis Pharmaceuticals· Source

• Completed

  LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

  NCT01828099· Phase 3· Novartis Pharmaceuticals· Source